Cardiff Oncology, Inc. (DE:XE7C)

Cardiff Oncology (XE7C) Cash flow


Cardiff Oncology Cash Flow

DE:XE7C's free cash flow for Q4 2023 was $-7.15M. For the 2023 fiscal year, DE:XE7C's free cash flow was decreased by $3.36M and operating cash flow was $-7.14M. See a summary of the company’s cash flow.
Cash Flow
Dec 23Dec 22Dec 21Dec 20Dec 19
Operating Cash Flow
$ -30.89M$ -30.89M$ -33.82M$ -23.04M$ -16.32M$ -13.27M
Investing Cash Flow
$ 36.20M$ 36.20M$ 38.15M$ -131.45M$ -211.00K$ -67.62K
Financing Cash Flow
--$ 75.00K$ 35.45M$ 137.31M$ 12.08M
Cash Flow From Discontinued Operation
Other Cash Adjustment Inside Changein Cash
End Cash Position
$ 71.27M$ 21.66M$ 16.35M$ 11.94M$ 130.98M$ 10.20M
Income Tax Paid Supplemental Data
$ 1.00K$ 1.00K$ 2.00K$ 1.00K$ 1.00K$ 800.00
Interest Paid Supplemental Data
-----$ 0.00
Issuance Of Capital Stock
---$ 34.19M$ 112.30M$ 8.82M
Issuance Of Debt
----$ 305.00K$ 0.00
Repayment Of Debt
----$ -305.00K$ 0.00
Free Cash Flow
$ -31.47M$ -31.47M$ -34.83M$ -23.25M$ -16.53M$ -13.34M
Domestic Sales
Foreign Sales
Currency in USD

Cardiff Oncology Cash Flow

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis